HEPA
Hepion Pharmaceuticals Inc. · NASDAQ
Hepion Pharmaceuticals Inc. (HEPA) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 12 wire items for HEPA, including 9 insider trades, 2 market updates and 1 press release or news item. The most recent was published Oct 27, 2026.
News · 26 weeks500%
2026-05-242026-11-15
Mix3590d
- Insider21(60%)
- SEC Filings7(20%)
- Other4(11%)
- Market3(9%)
Activity · 52 weeks6834 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- INSIDERSEC Form 4 filed by Hepion Pharmaceuticals Inc.4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- INSIDERSEC Form 4 filed by Hepion Pharmaceuticals Inc.4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- INSIDERSEC Form 4 filed by Hepion Pharmaceuticals Inc.4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- INSIDERSEC Form 4 filed by Hepion Pharmaceuticals Inc.4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- INSIDERSEC Form 4 filed by Hepion Pharmaceuticals Inc.4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- INSIDERSEC Form 4 filed by Hepion Pharmaceuticals Inc.4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- INSIDERSEC Form 4 filed by Hepion Pharmaceuticals Inc.4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- INSIDERSEC Form 4 filed by Hepion Pharmaceuticals Inc.4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- NEWSHepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac Arrest- In a simulation of 200 virtual subjects, a single dose of GV104 (16 mg nalmefene buccal film) taken at least 15 minutes before exposure prevented every potential fentanyl-induced cardiac arrest, at intravenous fentanyl doses known to be lethal in humans -- FDA re-affirmed the overall approach and provided comments that will improve the Company's ability to "demonstrate long-term prophylactic protection" -- The FDA comments are an important step in the path leading to an NDA. The Company intends to submit its response promptly - RED BANK, NJ / ACCESS Newswire / October 26, 2026 / Hepion Pharmaceuticals, Inc. (OTCQB:HEPA) ("Hepion" or the "Company"), a biotechnology company developing
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Hepion Pharmaceuticals Inc.SCHEDULE 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
- INSIDERSEC Form 3 filed by Hepion Pharmaceuticals Inc.3 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- NEWSHepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication- FDA's Division of Psychiatry issued written responses to a Type B pre-IND meeting request covering the regulatory pathway, the nonclinical package, and the design of a planned Phase 2 study-- Confirmed that the nonclinical and manufacturing data already on file under an IND may be cross-referenced to the new program, and stated that a planned Phase 2 proof-of-concept design is, in general, appropriate -- There are no FDA-approved medications for gambling disorder; Company anticipates filing an IND for GV104 and commencing the path toward a Phase 2 study in 2027 - RED BANK, NJ / ACCESS Newswire / October 19, 2026 / Hepion Pharmaceuticals, Inc. (OTCQB:HEPA) ("Hepion" or the "Company"),
- SECSEC Form S-8 filed by Hepion Pharmaceuticals Inc.S-8 - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- NEWSHepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update- Acquisition adds GV104, a clinical-stage opioid countermeasure with a 505(b)(2) pathway and an active investigational new drug application, and GV023, an oral formulation of an approved anti-TNF antibody -- FDA has stated in writing that additional clinical studies do not appear to be necessary to define the prophylactic dosing window for GV104, placing the critical path in manufacturing rather than in new clinical work -- Transaction creates a three-program portfolio spanning therapeutics and diagnostics, and Hepion intends to advance its circulating tumor RNA diagnostic toward a laboratory-developed test in 2027 - RED BANK, NJ / ACCESS Newswire / October 14, 2026 / Hepion Pharmaceu
- SECSEC Form 8-K filed by Hepion Pharmaceuticals Inc.8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- INSIDERDirector Fisher Danina bought $10,000 worth of shares (200,000 units at $0.05) (SEC Form 4)4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- SECHepion Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECHepion Pharmaceuticals Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- INSIDERNew insider Ki Holdings, Ltd. claimed ownership of 10,000,000 shares (SEC Form 3)3 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Hepion Pharmaceuticals Inc.SCHEDULE 13G - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
- INSIDERSEC Form 4 filed by Executive Chairman Lopriore Vincent S4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- SECSEC Form DEF 14C filed by Hepion Pharmaceuticals Inc.DEF 14C - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- INSIDERSEC Form 4 filed by Director Purcell Michael J.4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- SECHepion Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECHepion Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
HEPA FAQ
7 questionsWhat does Hepion Pharmaceuticals Inc. do?
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.What is the latest news on HEPA?
In the last 30 days Quantisnow tracked 12 wire items for HEPA: 9 insider trades, 2 market updates and 1 press release or news item. The most recent was published on October 27, 2026.Where does HEPA stock trade?
Hepion Pharmaceuticals Inc. (HEPA) is listed on NASDAQ.What sector and industry is HEPA in?
Hepion Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about HEPA?
Hepion Pharmaceuticals Inc. has had 1 recent analyst action on file. The most recent action was from Cantor Fitzgerald: Overweight with a $3.50 price target on 2022-02-28. Recent price targets cluster around $3.50.What companies are similar to HEPA?
Notable peers in the same industry include MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories). Compare HEPA side-by-side with any of them on Quantisnow.How can I track HEPA on Quantisnow?
Quantisnow aggregates Hepion Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HEPA to receive live email and push alerts on every new disclosure.